Core Viewpoint - The National Healthcare Security Administration (NHSA) has announced the preliminary review results for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, along with the commercial insurance innovative drug catalog, indicating a significant increase in the number of drugs under review and the introduction of a new commercial insurance category for innovative drugs [1][3]. Group 1: Drug Catalog Submission and Review - A total of 718 submissions were received for the basic medical insurance catalog, involving 633 drug generic names, with 534 passing the preliminary review [3]. - For the commercial insurance innovative drug catalog, 141 submissions were received, involving 141 drug generic names, with 121 passing the preliminary review, including 79 drugs that may be negotiated under both insurance schemes [3][4]. Group 2: Impact on the Pharmaceutical Industry - The introduction of the commercial insurance innovative drug catalog is expected to create new pathways for multi-channel payment for innovative drugs and promote collaboration between commercial insurance and basic medical insurance [3]. - The review process for drugs that have passed the preliminary review does not guarantee inclusion in the final catalog, as they must undergo strict evaluation and successful negotiations [4]. Group 3: Notable Drugs and Categories - The commercial insurance catalog includes 12 monoclonal antibodies, 3 CAR-T therapies, and other innovative drugs, with notable products like CAR-T therapies and PD-1 inhibitors included [5][6]. - There are 42 drugs that only passed the preliminary review for the commercial insurance catalog, primarily from major pharmaceutical companies [6]. Group 4: Future Negotiation Timeline - The NHSA plans to conduct negotiations for the 2025 insurance catalog between September and October, with results expected to be announced between October and November [7].